Crizotinib in the treatment of non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 5, 2013, Pages 473-480

  Rothschild, Sacha I ^a   Gautschi, Oliver ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Medical Oncology   (Switzerland)

Author keywords

Anaplastic lymphoma kinase; EML4 ALK; ROS1; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; PEMETREXED;

ANTINEOPLASTIC ACTIVITY; BILIRUBIN BLOOD LEVEL; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE FUSION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; IC 50; KIDNEY CYST; LIGHT ADAPTATION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); ONCOGENE; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TESTOSTERONE BLOOD LEVEL; VISUAL DISORDER;

ANAPLASTIC LYMPHOMA KINASE; EML4-ALK; ROS1; TARGETED THERAPY; TYROSINE KINASE INHIBITOR;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES;

EID: 84883774587     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.04.006     Document Type: Review

References (94)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
2. D.R. Aberle, A.M. Adams, and C.D. Berg Reduced lung-cancer mortality with low-dose computed tomographic screening N Engl J Med 365 2011 395 409
3. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
4. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
5. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
6. W. Pao, V. Miller, and M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311
7. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
8. J.Y. Han, K. Park, and S.W. Kim First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol 30 2012 1122 1128
9. T. Mitsudomi, S. Morita, and Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
10. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
11. C. Zhou, Y.L. Wu, and G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
12. R. Rosell, E. Carcereny, and R. Gervais Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
13. J.C. Yang, M.H. Schuler, and N. Yamamoto LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations J Clin Oncol 30 suppl 2012 (abstract LBA7500)
14. W. Pao, and N. Girard New driver mutations in non-small-cell lung cancer Lancet Oncol 12 2011 175 180
15. G. Bronte, S. Rizzo, and L. La Paglia Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma Cancer Treat Rev 36 suppl 3 2010 S21 S29
16. K. Garber ALK, lung cancer, and personalized therapy: portent of the future? J Natl Cancer Inst 102 2010 672 675
17. F. Janku, D.J. Stewart, and R. Kurzrock Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 7 2010 401 414
18. S.W. Morris, M.N. Kirstein, and M.B. Valentine Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma Science 263 1994 1281 1284
19. M. Soda, Y.L. Choi, and M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
20. M. Soda, S. Takada, and K. Takeuchi A mouse model for EML4-ALK-positive lung cancer Proc Natl Acad Sci U S A 105 2008 19893 19897
21. K. Rikova, A. Guo, and Q. Zeng Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
22. S.W. Morris, C. Naeve, and P. Mathew ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) Oncogene 14 1997 2175 2188
23. T. Iwahara, J. Fujimoto, and D. Wen Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system Oncogene 14 1997 439 449
24. Y.P. Mosse, M. Laudenslager, and L. Longo Identification of ALK as a major familial neuroblastoma predisposition gene Nature 455 2008 930 935
25. Y. Chen, J. Takita, and Y.L. Choi Oncogenic mutations of ALK kinase in neuroblastoma Nature 455 2008 971 974
26. R.E. George, T. Sanda, and M. Hanna Activating mutations in ALK provide a therapeutic target in neuroblastoma Nature 455 2008 975 978
27. I. Janoueix-Lerosey, D. Lequin, and L. Brugieres Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma Nature 455 2008 967 970
28. S. Zhang, F. Wang, and J. Keats Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen Chem Biol Drug Des 78 2011 999 1005
29. U. McDermott, A.J. Iafrate, and N.S. Gray Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors Cancer Res 68 2008 3389 3395
30. J.P. Koivunen, C. Mermel, and K. Zejnullahu EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin Cancer Res 14 2008 4275 4283
31. G. Scagliotti, R.A. Stahel, and R. Rosell ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development Eur J Cancer 48 2012 961 973
32. L.V. Sequist, R.S. Heist, and A.T. Shaw Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice Ann Oncol 22 2011 2616 2624
33. A.T. Shaw, B.Y. Yeap, and M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
34. S.J. Rodig, M. Mino-Kenudson, and S. Dacic Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population Clin Cancer Res 15 2009 5216 5223
35. A. Yoshida, K. Tsuta, and H. Nakamura Comprehensive histologic analysis of ALK-rearranged lung carcinomas Am J Surg Pathol 35 2011 1226 1234
36. A. Yoshida, K. Tsuta, and S. Watanabe Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component Lung Cancer 72 2011 309 315
37. D.W. Wong, E.L. Leung, and K.K. So The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS Cancer 115 2009 1723 1733
38. R.C. Doebele, A.B. Pilling, and D.L. Aisner Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin Cancer Res 18 2012 1472 1482
39. J.E. Chaft, M.E. Arcila, and P.K. Paik Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling Mol Cancer Ther 11 2012 485 491
40. A.T. Shaw, B.Y. Yeap, and B.J. Solomon Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 2011 1004 1012
41. K. Takeuchi, Y.L. Choi, and M. Soda Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts Clin Cancer Res 14 2008 6618 6624
42. T. Sasaki, S.J. Rodig, and L.R. Chirieac The biology and treatment of EML4-ALK non-small cell lung cancer Eur J Cancer 46 2010 1773 1780
43. K. Takeuchi, M. Soda, and Y. Togashi RET, ROS1 and ALK fusions in lung cancer Nat Med 18 2012 378 381
44. K. Takeuchi, Y.L. Choi, and Y. Togashi KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer Clin Cancer Res 15 2009 3143 3149
45. D.W. Wong, E.L. Leung, and S.K. Wong A novel KIF5B-ALK variant in nonsmall cell lung cancer Cancer 117 2011 2709 2718
46. Y. Togashi, M. Soda, and S. Sakata KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only PLoS One 7 2012 e31323
47. Y. Jung, P. Kim, and J. Keum Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing Genes Chromosomes Cancer 51 2012 590 597
48. J.M. Boland, S. Erdogan, and G. Vasmatzis Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas Hum Pathol 40 2009 1152 1158
49. D.R. Camidge, S.A. Kono, and A. Flacco Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment Clin Cancer Res 16 2010 5581 5590
50. M. Salido, L. Pijuan, and L. Martinez-Aviles Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer J Thorac Oncol 6 2011 21 27
51. D.R. Camidge, M. Theodoro, and D.A. Maxson Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer Cancer 118 2012 4486 4494
52. M. Mino-Kenudson, L.R. Chirieac, and K. Law A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry Clin Cancer Res 16 2010 1561 1571
53. A. McLeer-Florin, D. Moro-Sibilot, and A. Melis Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study J Thorac Oncol 7 2012 348 354
54. J.H. Paik, G. Choe, and H. Kim Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization J Thorac Oncol 6 2011 466 472
55. E. Thunnissen, L. Bubendorf, and M. Dietel EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations Virchows Arch 461 2012 245 257
56. E.S. Yi, J.M. Boland, and J.J. Maleszewski Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH J Thorac Oncol 6 2011 459 465
57. P. Yang, K. Kulig, and A.M. Oliveira Anaplastic lymphoma kinase (ALK) status and clinical outcomes by IHC and FISH: a retrospective study of never-smoker, adenocarcinoma lung cancer cases Lung Cancer 71 suppl 2 2011 S26 S28
58. P.A. Just, A. Cazes, and A. Audebourg Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers Lung Cancer 76 2011 309 315
59. A. Yoshida, K. Tsuta, and H. Nitta Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas J Thorac Oncol 6 2011 1677 1686
60. H. Kim, S.B. Yoo, and J.Y. Choe Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression J Thorac Oncol 6 2011 1359 1366
61. H.Y. Zou, Q. Li, and J.H. Lee An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res 67 2007 4408 4417
62. J.J. Cui, M. Tran-Dube, and H. Shen Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J Med Chem 54 2011 6342 6363
63. J.G. Christensen, H.Y. Zou, and M.E. Arango Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol Cancer Ther 6 2007 3314 3322
64. D.B. Costa, S. Kobayashi, and S.S. Pandya CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib J Clin Oncol 29 2011 e443 e445
65. R. Katayama, A.T. Shaw, and T.M. Khan Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers Sci Transl Med 4 2012 120ra17
66. E.L. Kwak, D.R. Camidge, and J. Clark Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 J Clin Oncol 27 2009 (abstract 3509)
67. W. Tan, K.D. Wilner, and Y. Bang Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients J Clin Oncol 28 2010 (abstract 2596)
68. S.H. Ou, L. Bazhenova, and D.R. Camidge Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer J Thorac Oncol 5 2010 2044 2046
69. E.L. Kwak, Y.J. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
70. D.R. Camidge, Y. Bang, and E.L. Kwak Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) J Clin Oncol 29 suppl 2011 (abstract 2501)
71. D.R. Camidge, Y.J. Bang, and E.L. Kwak Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
72. D.W. Kim, M.J. Ahn, and Y. Shi Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) J Clin Oncol 30 suppl 2012 (abstract 7533)
73. L. Crinò, D. Kim, and G.J. Riely Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 J Clin Oncol 29 suppl 2011 (abstract 7514)
74. A.T. Shaw, D.W. Kim, and K. Nakagawa Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer N Engl J Med Jun 1, 2013 [e-pub ahead of print]
75. G. Scagliotti, N. Hanna, and F. Fossella The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 2009 253 263
76. A.J. Weickhardt, M.S. Rothman, and S. Salian-Mehta Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer Cancer 118 2012 5302 5309
77. B. Solomon, A. Chiappori, and A. Lamb Preliminary characterization of visual events reported by patients (Pts) receiving crizotinib for the treatment of advanced ALK-positive non-small cell lung cancer (NSCLC) Eur J Cancer 47 suppl 1 2011 (abstract 3030)
78. B. Besse, R. Salgia, and B. Solomon Visual disturbances in patients (pts) with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) treated with crizotinib Ann Oncol 23 suppl 9 2012 (abstract 1268P)
79. T. Sasaki, J. Koivunen, and A. Ogino A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res 71 2011 6051 6060
80. Y.L. Choi, M. Soda, and Y. Yamashita EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N Engl J Med 363 2010 1734 1739
81. C.M. Lovly, and W. Pao Escaping ALK inhibition: mechanisms of and strategies to overcome resistance Sci Transl Med 4 2012 120ps2
82. R. Katayama, T.M. Khan, and C. Benes Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK Proc Natl Acad Sci U S A 108 2011 7535 7540
83. O. Gautschi, H. Schefer, and C. Riklin Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer Onkologie 36 2013 342 347
84. R. Mehra, D.R. Camidge, and S. Sharma First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors J Clin Oncol 30 suppl 2012 (abstract 3007)
85. H. Sakamoto, T. Tsukaguchi, and S. Hiroshima CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant Cancer Cell 19 2011 679 690
86. C.M. Lovly, J.M. Heuckmann, and E. de Stanchina Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors Cancer Res 71 2011 4920 4931
87. L.V. Sequist, S. Gettinger, and N.N. Senzer Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer J Clin Oncol 28 2010 4953 4960
88. J. Tanizaki, I. Okamoto, and K. Okamoto MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations J Thorac Oncol 6 2011 1624 1631
89. Stutz E, Gautschi O, Fey MF, et al. Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET-targeting in oncology. In press.
90. J.K. Lennerz, E.L. Kwak, and A. Ackerman MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib J Clin Oncol 29 2011 4803 4810
91. S.H. Ou, E.L. Kwak, and C. Siwak-Tapp Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification J Thorac Oncol 6 2011 942 946
92. K. Bergethon, A.T. Shaw, and S.H. Ou ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 2012 863 870
93. V. Rimkunas, K. Crosby, and M. Kelly Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis J Clin Oncol 28 suppl 2010 (abstract 10536)
94. A.T. Shaw, D.R. Camidge, and J.A. Engelman Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement J Clin Oncol 30 suppl 2012 (abstract 7508)